Of note, there are also reports indicating that TAMs might limit anti-PD-1 treatments for example through preventing CD8+ T cells from reaching tumor cells (147) or by removing anti-PD-1 antibodies from T cells through Fc-Fcγ receptors binding (270), though the latter can be prevented by blocking Fc/Fcγ receptor interactions (270). This evidence concerns the gene CD8A and neoplasm.